Tags

Type your tag names separated by a space and hit enter

Brain derived neurotrophic factor Val66Met polymorphism and psychotic symptoms in Alzheimer's disease.

Abstract

OBJECTIVE

Alzheimer's disease (AD) is an irreversible, progressive neurodegenerative disorder with a high prevalence. Since behavioral disturbances, such as psychotic symptoms, represent a key feature of AD, genes related to dopamine, serotonin and brain derived neurotrophic factor (BDNF), are considered as candidate genes for AD. BDNF is a neurotrophin that regulates neurodevelopment, neuroplasticity, and neuronal functions. BDNF is involved in the etiopathogenesis of psychiatric and neurodegenerative disorders. A single base pair polymorphism (BDNF Val66Met) was reported to be associated with AD and/or schizophrenia, as well as other psychoses, although some studies failed to replicate these findings. The aim of the study was to evaluate the association between BDNF Val66Met variants and AD, as well as onset of AD or presence of psychotic symptoms in AD.

METHOD

BDNF Val66Met was analyzed in 211 patients with AD and in 402 aged healthy control subjects. All subjects were ethnically homogenous Caucasians from Croatia, and were subdivided according to the gender, onset of AD, and presence of psychotic symptoms. A χ(2) test, with Bonferroni correction and standardized residuals were used to evaluate the data.

RESULTS

Distribution of the BDNF Val66Met genotypes differed significantly between male and female AD patients with or without psychotic symptoms. This difference was due to the significant contribution of the Met/Val genotype and the combined Met/Met and Met/Val genotypes between psychotic and non-psychotic symptoms in male, but not in female patients with AD. The frequency of the gene variants of the BDNF Val66Met did not differ significantly among male and female patients with AD and control subjects, or between male and female patients with early or late onset AD. There were significant sex related differences in age, duration of illness and scores of dementia between patients with AD.

CONCLUSION

Our male patients were younger, had shorter duration of illness, and had less severe dementia and higher cognitive performance than female AD patients. The gene variants of the BDNF Val66Met polymorphism were significantly associated with the presence of psychotic symptoms in male, but not in female patients with AD. The results had adequate statistical power to suggest that BDNF Val66Met was not related to susceptibility to AD or the onset of AD, but that presence of one or two Met alleles of BDNF Val66Met polymorphism might present a risk factor for psychosis in AD.

Authors+Show Affiliations

Division of Molecular Medicine, Rudjer Boskovic Institute, Croatia. npivac@irb.hrNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21044653

Citation

Pivac, Nela, et al. "Brain Derived Neurotrophic Factor Val66Met Polymorphism and Psychotic Symptoms in Alzheimer's Disease." Progress in Neuro-psychopharmacology & Biological Psychiatry, vol. 35, no. 2, 2011, pp. 356-62.
Pivac N, Nikolac M, Nedic G, et al. Brain derived neurotrophic factor Val66Met polymorphism and psychotic symptoms in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(2):356-62.
Pivac, N., Nikolac, M., Nedic, G., Mustapic, M., Borovecki, F., Hajnsek, S., ... Muck Seler, D. (2011). Brain derived neurotrophic factor Val66Met polymorphism and psychotic symptoms in Alzheimer's disease. Progress in Neuro-psychopharmacology & Biological Psychiatry, 35(2), pp. 356-62. doi:10.1016/j.pnpbp.2010.10.020.
Pivac N, et al. Brain Derived Neurotrophic Factor Val66Met Polymorphism and Psychotic Symptoms in Alzheimer's Disease. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):356-62. PubMed PMID: 21044653.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Brain derived neurotrophic factor Val66Met polymorphism and psychotic symptoms in Alzheimer's disease. AU - Pivac,Nela, AU - Nikolac,Matea, AU - Nedic,Gordana, AU - Mustapic,Maja, AU - Borovecki,Fran, AU - Hajnsek,Sanja, AU - Presecki,Paola, AU - Pavlovic,Mladen, AU - Mimica,Ninoslav, AU - Muck Seler,Dorotea, Y1 - 2010/10/31/ PY - 2010/07/12/received PY - 2010/10/11/revised PY - 2010/10/22/accepted PY - 2010/11/4/entrez PY - 2010/11/4/pubmed PY - 2011/12/13/medline SP - 356 EP - 62 JF - Progress in neuro-psychopharmacology & biological psychiatry JO - Prog. Neuropsychopharmacol. Biol. Psychiatry VL - 35 IS - 2 N2 - OBJECTIVE: Alzheimer's disease (AD) is an irreversible, progressive neurodegenerative disorder with a high prevalence. Since behavioral disturbances, such as psychotic symptoms, represent a key feature of AD, genes related to dopamine, serotonin and brain derived neurotrophic factor (BDNF), are considered as candidate genes for AD. BDNF is a neurotrophin that regulates neurodevelopment, neuroplasticity, and neuronal functions. BDNF is involved in the etiopathogenesis of psychiatric and neurodegenerative disorders. A single base pair polymorphism (BDNF Val66Met) was reported to be associated with AD and/or schizophrenia, as well as other psychoses, although some studies failed to replicate these findings. The aim of the study was to evaluate the association between BDNF Val66Met variants and AD, as well as onset of AD or presence of psychotic symptoms in AD. METHOD: BDNF Val66Met was analyzed in 211 patients with AD and in 402 aged healthy control subjects. All subjects were ethnically homogenous Caucasians from Croatia, and were subdivided according to the gender, onset of AD, and presence of psychotic symptoms. A χ(2) test, with Bonferroni correction and standardized residuals were used to evaluate the data. RESULTS: Distribution of the BDNF Val66Met genotypes differed significantly between male and female AD patients with or without psychotic symptoms. This difference was due to the significant contribution of the Met/Val genotype and the combined Met/Met and Met/Val genotypes between psychotic and non-psychotic symptoms in male, but not in female patients with AD. The frequency of the gene variants of the BDNF Val66Met did not differ significantly among male and female patients with AD and control subjects, or between male and female patients with early or late onset AD. There were significant sex related differences in age, duration of illness and scores of dementia between patients with AD. CONCLUSION: Our male patients were younger, had shorter duration of illness, and had less severe dementia and higher cognitive performance than female AD patients. The gene variants of the BDNF Val66Met polymorphism were significantly associated with the presence of psychotic symptoms in male, but not in female patients with AD. The results had adequate statistical power to suggest that BDNF Val66Met was not related to susceptibility to AD or the onset of AD, but that presence of one or two Met alleles of BDNF Val66Met polymorphism might present a risk factor for psychosis in AD. SN - 1878-4216 UR - https://www.unboundmedicine.com/medline/citation/21044653/Brain_derived_neurotrophic_factor_Val66Met_polymorphism_and_psychotic_symptoms_in_Alzheimer's_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0278-5846(10)00406-9 DB - PRIME DP - Unbound Medicine ER -